Surrozen, Inc. announced that the first subject has been dosed in its two-part Phase 1 clinical trial for SZN-043 which is in development for the potential treatment of severe alcoholic hepatitis. The Phase 1, randomized, single and multiple ascending dose study will evaluate the safety, pharmacokinetics and activity of SZN-043. The first part of the trial will evaluate single doses of SZN-043 administered via intravenous injection or infusion in healthy volunteers, progressing from 3 mg through 30 mg.

The second part will evaluate multiple ascending doses of SZN-043 for a period of four weeks in patients with a documented history of liver cirrhosis and a Child-Pugh score between 5 and 7 at the 2 highest dose levels tolerated in part 1. The primary endpoint of the trial is safety and tolerability of SZN-043 and secondary outcomes include pharmacokinetics, pharmacodynamics markers as well as prevalence of Anti-Drug Antibodies (ADA).